We've found
1,052
archived clinical trials in
Nephrology
We've found
1,052
archived clinical trials in
Nephrology
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Updated: 12/31/1969
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Updated: 12/31/1969
An Open-Label Phase I/II Pilot Study to Assess the Safety/Tolerability and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Updated: 12/31/1969
An Open-Label Phase I/II Pilot Study to Assess the Safety/Tolerability and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Evaluation of Ureteral Stents in the Management of Stone Disease
Updated: 12/31/1969
Evaluation of Ureteral Stents in the Management of Stone Disease
Status: Enrolling
Updated: 12/31/1969
Evaluation of Ureteral Stents in the Management of Stone Disease
Updated: 12/31/1969
Evaluation of Ureteral Stents in the Management of Stone Disease
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
ATHENA: Natural History of Disease Study in Alport Syndrome Patients
Updated: 12/31/1969
A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Rituximab and Belimumab for Lupus Nephritis
Updated: 12/31/1969
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
Updated: 12/31/1969
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy
Status: Enrolling
Updated: 12/31/1969
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
Updated: 12/31/1969
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
Updated: 12/31/1969
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy
Status: Enrolling
Updated: 12/31/1969
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
Updated: 12/31/1969
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
Updated: 12/31/1969
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy
Status: Enrolling
Updated: 12/31/1969
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
Updated: 12/31/1969
Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Updated: 12/31/1969
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Status: Enrolling
Updated: 12/31/1969
Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Updated: 12/31/1969
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Updated: 12/31/1969
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Status: Enrolling
Updated: 12/31/1969
Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Updated: 12/31/1969
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Updated: 12/31/1969
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Status: Enrolling
Updated: 12/31/1969
Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Updated: 12/31/1969
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Updated: 12/31/1969
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Status: Enrolling
Updated: 12/31/1969
Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Updated: 12/31/1969
An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome
Updated: 12/31/1969
Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome (RAMP)
Status: Enrolling
Updated: 12/31/1969
Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome
Updated: 12/31/1969
Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome (RAMP)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
TCUPS- Tolvaptan Use in Cyctinuria and Urolithiasis: A Pilot Study
Updated: 12/31/1969
Use of Tolvaptan, a Vasopressin Antagonist, to Increase Urine Dilution and Reduce Cystine Urolithiasis Among Patients With Homozygous Cystinuria: a Pilot Investigation
Status: Enrolling
Updated: 12/31/1969
TCUPS- Tolvaptan Use in Cyctinuria and Urolithiasis: A Pilot Study
Updated: 12/31/1969
Use of Tolvaptan, a Vasopressin Antagonist, to Increase Urine Dilution and Reduce Cystine Urolithiasis Among Patients With Homozygous Cystinuria: a Pilot Investigation
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials